This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
The first-of-its-kind gene-editing tool for sickle cell disease was accelerated to market through a regulatory initiative.
The MHRA said it needed to assess data from multiple sources before adding warnings to COVID shots.
